PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer
This Special Issue of Cancers contains research and review articles on “PARPs, PAR and NAD metabolism and their inhibitors in Cancer”. It focuses on selected papers from the PARP2019 conference on “New Avenues in Basic and Translational PARP research”, that took place in Budapest (Hungary), on 20–23...
Guardado en:
| Formato: | Online |
|---|---|
| Lenguaje: | inglés |
| Publicado: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Materias: | |
| Acceso en línea: | ONIX_20230808_9783036581569_37 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1869517263291285504 |
|---|---|
| collection | Directory of Open Access Books |
| description | This Special Issue of Cancers contains research and review articles on “PARPs, PAR and NAD metabolism and their inhibitors in Cancer”. It focuses on selected papers from the PARP2019 conference on “New Avenues in Basic and Translational PARP research”, that took place in Budapest (Hungary), on 20–23 May 2019. |
| format | Online |
| id | doab-20.500.12854ir-112469 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1124692024-03-28T03:31:10Z PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer Curtin, Nicola Bay, Péter MDS PARP inhibitors olaparib hematopoietic differentiation PARP1 AML poly-ADP-ribose polymerase 1 (PARP1) brahma-related gene 1 (BRG1) histone acetyltransferase p300 (EP300) gene transcription cancer cell head and neck squamous cell carcinoma CAL27 SCC90 p60/p150 CAF-1 subunits DNA repair homologous recombination biomarkers personalized treatment UVB PARP mitochondria metabolism biogenesis autophagy carcinogenesis transcription PARylation DNA damage transcription silencing carryover effect TOP1 activity TDP1 irinotecan immunomodulation tumor microenvironment trapping cancer therapeutic strategy arginine-specific mono-ADP-ribosylation bacterial toxin cholera toxin ART1 ARH1 tumorigenesis loss of heterozygosity membrane repair gender bias Syk EGFR squamous cell carcinoma PARP-Akt interplay PI3K mTOR cytoprotection apoptosis resistance oxidative stress mitochondrial protection drug development synthetic lethality clinical trials ADP-ribosylation cancer macrodomain ADP-ribosyl hydrolase ARTD MACROD1 MACROD2 TARG1 ATM ATR PARP inhibitor prostate cancer pancreatic cancer lung cancer Tumor microenvironment PARPs hypoxia CHK1 replication stress homologous recombination DNA repair cell cycle cytotoxicity PARP Inhibitors beta-lapachone NQO1 PARG NAMPT cancer therapeutics cMET poly (ADP-ribose) glycohydrolase radiosensitization poly (ADP-ribose) polymerase ES cells poly (ADP-ribose) polymerase inhibitors (PARPi) ataxia telangiectasia and Rad3 related inhibitors (ATRi) cell cycle checkpoints NAD+ NMNAT1 cisplatin chemotherapy apoptosis osteosarcoma DNA damage response immunotherapy immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 combination therapy solid tumors the PARP inhibitor PJ34 distorted mitotic spindles exclusive eradication of human cancer cells nucleolus poly(ADP-ribosyl)ation ARTDs n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSB Biochemistry This Special Issue of Cancers contains research and review articles on “PARPs, PAR and NAD metabolism and their inhibitors in Cancer”. It focuses on selected papers from the PARP2019 conference on “New Avenues in Basic and Translational PARP research”, that took place in Budapest (Hungary), on 20–23 May 2019. 2023-08-08T15:13:37Z 2023-08-08T15:13:37Z 2023 book ONIX_20230808_9783036581569_37 9783036581569 9783036581576 https://directory.doabooks.org/handle/20.500.12854/112469 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/7584 https://mdpi.com/books/pdfview/book/7584 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-8157-6 10.3390/books978-3-0365-8157-6 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036581569 9783036581576 462 Basel open access |
| spellingShingle | MDS PARP inhibitors olaparib hematopoietic differentiation PARP1 AML poly-ADP-ribose polymerase 1 (PARP1) brahma-related gene 1 (BRG1) histone acetyltransferase p300 (EP300) gene transcription cancer cell head and neck squamous cell carcinoma CAL27 SCC90 p60/p150 CAF-1 subunits DNA repair homologous recombination biomarkers personalized treatment UVB PARP mitochondria metabolism biogenesis autophagy carcinogenesis transcription PARylation DNA damage transcription silencing carryover effect TOP1 activity TDP1 irinotecan immunomodulation tumor microenvironment trapping cancer therapeutic strategy arginine-specific mono-ADP-ribosylation bacterial toxin cholera toxin ART1 ARH1 tumorigenesis loss of heterozygosity membrane repair gender bias Syk EGFR squamous cell carcinoma PARP-Akt interplay PI3K mTOR cytoprotection apoptosis resistance oxidative stress mitochondrial protection drug development synthetic lethality clinical trials ADP-ribosylation cancer macrodomain ADP-ribosyl hydrolase ARTD MACROD1 MACROD2 TARG1 ATM ATR PARP inhibitor prostate cancer pancreatic cancer lung cancer Tumor microenvironment PARPs hypoxia CHK1 replication stress homologous recombination DNA repair cell cycle cytotoxicity PARP Inhibitors beta-lapachone NQO1 PARG NAMPT cancer therapeutics cMET poly (ADP-ribose) glycohydrolase radiosensitization poly (ADP-ribose) polymerase ES cells poly (ADP-ribose) polymerase inhibitors (PARPi) ataxia telangiectasia and Rad3 related inhibitors (ATRi) cell cycle checkpoints NAD+ NMNAT1 cisplatin chemotherapy apoptosis osteosarcoma DNA damage response immunotherapy immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 combination therapy solid tumors the PARP inhibitor PJ34 distorted mitotic spindles exclusive eradication of human cancer cells nucleolus poly(ADP-ribosyl)ation ARTDs n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSB Biochemistry PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer |
| title | PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer |
| title_full | PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer |
| title_fullStr | PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer |
| title_full_unstemmed | PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer |
| title_short | PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer |
| title_sort | parps par and nad metabolism and their inhibitors in cancer |
| topic | MDS PARP inhibitors olaparib hematopoietic differentiation PARP1 AML poly-ADP-ribose polymerase 1 (PARP1) brahma-related gene 1 (BRG1) histone acetyltransferase p300 (EP300) gene transcription cancer cell head and neck squamous cell carcinoma CAL27 SCC90 p60/p150 CAF-1 subunits DNA repair homologous recombination biomarkers personalized treatment UVB PARP mitochondria metabolism biogenesis autophagy carcinogenesis transcription PARylation DNA damage transcription silencing carryover effect TOP1 activity TDP1 irinotecan immunomodulation tumor microenvironment trapping cancer therapeutic strategy arginine-specific mono-ADP-ribosylation bacterial toxin cholera toxin ART1 ARH1 tumorigenesis loss of heterozygosity membrane repair gender bias Syk EGFR squamous cell carcinoma PARP-Akt interplay PI3K mTOR cytoprotection apoptosis resistance oxidative stress mitochondrial protection drug development synthetic lethality clinical trials ADP-ribosylation cancer macrodomain ADP-ribosyl hydrolase ARTD MACROD1 MACROD2 TARG1 ATM ATR PARP inhibitor prostate cancer pancreatic cancer lung cancer Tumor microenvironment PARPs hypoxia CHK1 replication stress homologous recombination DNA repair cell cycle cytotoxicity PARP Inhibitors beta-lapachone NQO1 PARG NAMPT cancer therapeutics cMET poly (ADP-ribose) glycohydrolase radiosensitization poly (ADP-ribose) polymerase ES cells poly (ADP-ribose) polymerase inhibitors (PARPi) ataxia telangiectasia and Rad3 related inhibitors (ATRi) cell cycle checkpoints NAD+ NMNAT1 cisplatin chemotherapy apoptosis osteosarcoma DNA damage response immunotherapy immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 combination therapy solid tumors the PARP inhibitor PJ34 distorted mitotic spindles exclusive eradication of human cancer cells nucleolus poly(ADP-ribosyl)ation ARTDs n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSB Biochemistry |
| topic_facet | MDS PARP inhibitors olaparib hematopoietic differentiation PARP1 AML poly-ADP-ribose polymerase 1 (PARP1) brahma-related gene 1 (BRG1) histone acetyltransferase p300 (EP300) gene transcription cancer cell head and neck squamous cell carcinoma CAL27 SCC90 p60/p150 CAF-1 subunits DNA repair homologous recombination biomarkers personalized treatment UVB PARP mitochondria metabolism biogenesis autophagy carcinogenesis transcription PARylation DNA damage transcription silencing carryover effect TOP1 activity TDP1 irinotecan immunomodulation tumor microenvironment trapping cancer therapeutic strategy arginine-specific mono-ADP-ribosylation bacterial toxin cholera toxin ART1 ARH1 tumorigenesis loss of heterozygosity membrane repair gender bias Syk EGFR squamous cell carcinoma PARP-Akt interplay PI3K mTOR cytoprotection apoptosis resistance oxidative stress mitochondrial protection drug development synthetic lethality clinical trials ADP-ribosylation cancer macrodomain ADP-ribosyl hydrolase ARTD MACROD1 MACROD2 TARG1 ATM ATR PARP inhibitor prostate cancer pancreatic cancer lung cancer Tumor microenvironment PARPs hypoxia CHK1 replication stress homologous recombination DNA repair cell cycle cytotoxicity PARP Inhibitors beta-lapachone NQO1 PARG NAMPT cancer therapeutics cMET poly (ADP-ribose) glycohydrolase radiosensitization poly (ADP-ribose) polymerase ES cells poly (ADP-ribose) polymerase inhibitors (PARPi) ataxia telangiectasia and Rad3 related inhibitors (ATRi) cell cycle checkpoints NAD+ NMNAT1 cisplatin chemotherapy apoptosis osteosarcoma DNA damage response immunotherapy immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 combination therapy solid tumors the PARP inhibitor PJ34 distorted mitotic spindles exclusive eradication of human cancer cells nucleolus poly(ADP-ribosyl)ation ARTDs n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSB Biochemistry |
| url | ONIX_20230808_9783036581569_37 |